MedTrace Logo

A Study of JNJ-90301900 in Combination With Chemoradiation Followed by Consolidation Immunotherapy for Non-Small Cell Lung Cancer (NSCLC)

NCT06667908 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2026-05-11

No results posted yet for this study

Summary

The purpose of this study is to determine whether JNJ-90301900 added to concurrent platinum-based doublet chemotherapy with radiation therapy (cCRT) followed by consolidation immunotherapy (cIT) can improve objective response rate (ORR; that is percentage of participants whose best response is complete response or partial response during the study) in participants with locally advanced and unresectable stage III non-small cell lung cancer.

Conditions

  • Carcinoma, Non-Small-Cell Lung

Interventions

DRUG

JNJ-90301900

JNJ-90301900 will be injected intratumorally and/or intranodally.

BIOLOGICAL

Durvalumab

Durvalumab will be administered as intravenous (IV) infusion as cIT.

RADIATION

Concurrent Chemo/Radiation Therapy (cCRT)

Radiation by intensity modulated radiation therapy (IMRT) will be administered.

DRUG

Concurrent Chemo/Radiation Therapy (cCRT): Carboplatin

Carboplatin will be administered as IV infusion as platinum-based doublet chemotherapy.

DRUG

Concurrent Chemo/Radiation Therapy (cCRT): Paclitaxel

Paclitaxel will be administered as IV infusion as platinum-based doublet chemotherapy.

Sponsors & Collaborators

  • Johnson & Johnson Enterprise Innovation Inc.

    lead INDUSTRY

Principal Investigators

  • Johnson & Johnson Enterprise Innovation Inc. Clinical Trial · Johnson & Johnson Enterprise Innovation Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-12-06
Primary Completion
2028-12-31
Completion
2028-12-31
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Brazil
  • China
  • France
  • Hong Kong
  • Netherlands
  • Spain
  • Turkey (Türkiye)
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06667908 on ClinicalTrials.gov